Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis

Cardiovascular Research

Volumn 99, Issue 2, 2013, Pages 364-373

  Lundberg, Anna M ^a   Ketelhuth, Daniel F J ^a   Johansson, Maria E ^b   Gerdes, Norbert ^c   Liu, Sang ^a   Yamamoto, Masahiro ^d   Akira, Shizuo ^d   Hansson, Göran K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; TLR3; TRAM; TRIF; Vascular inflammation

Indexed keywords

TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMATOPOIETIC CELL; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ATHEROSCLEROSIS; TLR3; TRAM; TRIF; VASCULAR INFLAMMATION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ATHEROSCLEROSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-1; RECEPTORS, LDL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TIME FACTORS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4;

EID: 84878805816     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt033     Document Type: Article

References (30)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695
2. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol 2010;134:5-24
3. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. Circulation 2002;105:1158-1161 (Pubitemid 34225814)
4. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005;115:3149-3156 (Pubitemid 41567579)
5. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM et al. Lack of Tolllike receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101:10679-10684 (Pubitemid 38955802)
6. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801 (Pubitemid 43261452)
7. Michelsen KS, Aicher A, Mohaupt M, Hartung T, Dimmeler S, Kirschning CJ et al. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem 2001;276:25680-25686
8. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004;10:416-421 (Pubitemid 38508522)
9. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998;102:910-918 (Pubitemid 28419236)
10. Zhang L, Ovchinnikova O, Jonsson A, Lundberg AM, Berg M, Hansson GK et al. The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J 2012;33:2025-2034
11. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: An update. Arterioscler Thromb Vasc Biol 2008;28:1897-1908
12. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A et al. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 2008;28:1090-1096
13. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006;113:2301-2312 (Pubitemid 43947976)
14. McAleer JP, Rossi RJ, Vella AT. Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF. J Immunol 2009;182:5322-5330
15. Goossens P, Gijbels MJ, Zernecke A, EijgelaarW, Vergouwe MN, van der Made I et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 2010;12:142-153
16. Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, Seya T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta. J Biol Chem 2003;278:49751-49762 (Pubitemid 37548808)
17. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT. Selective TRIF-Dependent signaling by a synthetic Toll-like receptor 4 agonist. Science Signal 2012;5:ra13
18. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-Dependent and -independent cytokine secretion induced by minimally oxidized low-Density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005; 25:1213-1219 (Pubitemid 40776611)
19. Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med 2008;205:2609-2621
20. Kariko K, Ni H, Capodici J, Lamphier M,Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004;279:12542-12550 (Pubitemid 38445825)
21. Beetz S,Wesch D, Marischen L,Welte S, Oberg HH, Kabelitz D. Innate immune functions of human gammadelta T cells. Immunobiology 2008;213:173-182 (Pubitemid 351484782)
22. Meyer T, Oberg HH, Peters C, Martens I, Adam-Klages S, Kabelitz D et al. poly(I:C) costimulation induces a stronger antiviral chemokine and granzyme B release in human CD4 T cells than CD28 costimulation. J Leukoc Biol 2012;92:765-774
23. Elhage R, Gourdy P, Brouchet L, Jawien J, Fouque MJ, Fievet C et al. Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-Deficient mice. Am J Pathol 2004; 165:2013-2018 (Pubitemid 39578379)
24. Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT et al. From the cover: Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 2011;108:2372-2377
25. Zimmer S, Steinmetz M, Asdonk T, Motz I, Coch C, Hartmann E et al. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res 2011; 108:1358-1366
26. Richards MR, Black AS, Bonnet DJ, Barish GD, Woo CW, Tabas I et al. The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice. Innate Immun 2013;19:20-9
27. Lundberg AM, Drexler SK, Monaco C, Williams LM, Sacre SM, Feldmann M et al. Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: A phenomenon absent from murine cell systems. Blood 2007;110:3245-3252 (Pubitemid 350106317)
28. Ahmad U, Ali R, Lebastchi AH, Qin L, Lo SF, Yakimov AO et al. IFN-gamma primes intact human coronary arteries and cultured coronary smooth muscle cells to doublestranded RNA-And self-RNA-induced inflammatory responses by upregulating TLR3 and melanoma differentiation-Associated gene 5. J Immunol 2010;185:1283-1294
29. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738 (Pubitemid 33009951)
30. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003;12:805-816 (Pubitemid 37352775)